Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis - Wikidata - wikimedia - TriplyDB

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

http://www.wikidata.org/entity/Q24243219

about

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Helminths for induction of remission in inflammatory bowel disease Probiotics for maintenance of remission in ulcerative colitis Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis Oral budesonide for induction of remission in ulcerative colitis Oral budesonide for induction of remission in ulcerative colitis Type I interferons for induction of remission in ulcerative colitis Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis Methotrexate for induction of remission in ulcerative colitis Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease Therapeutic drug monitoring in inflammatory bowel disease Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid Undue reliance on I(2) in assessing heterogeneity may mislead The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario.Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.European evidence-based Consensus on the management of ulcerative colitis: Current management.Patient preferences for surgical versus medical therapy for ulcerative colitis.Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain Ulcerative colitis: current treatment strategies and future prospects.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine Pros and cons of medical management of ulcerative colitis.Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis Ulcerative Colitis: Update on Medical Management.Emerging drugs for the treatment of ulcerative colitis Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism.Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.Management of distal ulcerative colitis: frequently asked questions analysis.Drivers of cost after surgical and medical therapy for chronic ulcerative colitis: a nested case-cohort study in Olmsted County, Minnesota Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.Are we giving azathioprine too much time?A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody.Immunomodulators for all patients with inflammatory bowel disease?Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study.

P2860

Q24185761-C32A6067-96F8-4173-AC71-1891B9448789 Q24200757-9CA5C76C-ADB5-4E35-8DC6-484B1248A8D6 Q24234013-588E6D28-1E62-4BCA-9501-A87507EDD7AF Q24234400-577C0ED9-05B6-45F7-BB95-C3D3AC24C07E Q24234403-5A8ECECA-5C4A-45F7-90BB-52FDB1D92985 Q24234633-EBBF1931-5434-4075-A7FD-AE07F207F172 Q24240602-868863F7-3985-4E39-92C7-8D9D19F3F470 Q24241993-8A625711-73BB-4AD6-8FA7-5FE334BC1739 Q24243052-C57E270E-E4C2-41AE-8AF2-E5D37F2EBF2D Q24243284-B7E4F5A5-2ABA-4A23-B9D7-B0BBBD544B06 Q24244006-2D4886DE-633E-4903-AD9B-6A966D39C4EB Q24631869-87C7DD85-EBAF-4EB7-8B08-51438237E492 Q26852729-A1BA39F0-D300-4754-A61E-71C835AD03ED Q28486322-D15E4F3F-C2B0-4232-8219-16879FF3CFB6 Q28538238-54773D5E-1E50-4881-8E67-30265A6E75EF Q33387460-CC16D2F8-F273-499E-808E-5435C6CFF6B6 Q33536129-EE6169BF-BCCE-4D02-B84C-300ED68D9CDE Q33590827-36B9BB9B-F25D-4E72-B845-613906D1BE8D Q33819473-82BE2CB4-120C-4992-8F7C-AC3E6D577E4F Q34025054-FDD2411F-0E8B-4AB9-898C-49EC27CE0C9E Q34065549-CC4598B5-8C76-4864-AE39-EF96BA4EA9B8 Q34326911-F43157AE-0BB0-4E51-809B-6F1D24293B80 Q34408967-DDE8A378-67FD-4F96-820A-2AAC393F18C6 Q35026302-2F619D12-6398-44BA-98C6-89A9A1855BD9 Q35036160-E560B9DB-3A0A-4217-92D3-2EFEB3E0514A Q35100726-11E5CEE2-E689-4FB5-9A06-AF19AB3A5BA3 Q35777883-35AF791C-D519-457A-85D6-510C9CD582D4 Q35781294-7D5AA2E7-52A2-4AC9-9236-D5C09A205EE8 Q36039436-A41B0FC8-D4C4-44A3-B3D1-02ED846794D7 Q36302849-B93FDB6F-E166-424E-B4C5-22BA16E17C70 Q36650158-1C73F539-8BF2-44C0-AEB7-D108761DB7EE Q36815176-9ACC1269-9F52-47D2-8679-0F20BDB7B0FC Q37091094-054FF3EE-421A-42C0-A613-7EFE52EFAD3A Q37131424-01B7D72C-CA18-4DE0-B486-2112DFDD9E72 Q37276962-AD45CB3A-7652-46C3-B7BB-0C201B7F7715 Q37276966-D25533F1-4120-42B2-B728-D3037B08C4E3 Q37413254-57379E19-0C6E-4233-8A5E-C066BD18F92E Q37823320-EC3F62D5-54AB-4656-9F96-092704B96E93 Q38112106-45482A61-B5FD-4747-813C-48F6D5C6FF04 Q38609051-9CDE15C8-0BA1-4744-B24D-7F92DFC2AA8E

P2860

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

http://www.wikidata.org/entity/Q24243219

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@ast

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en-gb

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@nl

type

label

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@ast

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en-gb

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@nl

prefLabel

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@ast

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en-gb

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@nl

P1433

Q24243219-E157BE82-01F7-452D-B78C-AE4F3A09890E

P1476

Q24243219-8C06DF7D-C63B-4B99-9F54-AA9A6724ED21

P2093

Q24243219-DAAE68ED-06D4-44FB-BF2D-77EB054C7B2D

Q24243219-F9E16D5F-7D08-4CE1-8107-7E996062EBFE

P2860

Q24243219-120FECB7-D74D-4E7B-A6FD-23DA4D07D406

Q24243219-20429577-6AA7-4893-B6D8-D52BE2011CC0

Q24243219-205CDA4C-54C6-4C7F-90C4-927A21A0839F

Q24243219-21DDAD61-592B-4856-867B-7D3EE4CA9B88

Q24243219-29C796EB-96F3-40D1-8951-47C840E18949

Q24243219-3570C415-EF5E-4DFB-9F00-CF4CC4E72D2B

Q24243219-4A506AD9-94BA-472B-81DD-911FEC5FF8BD

Q24243219-4A5E3BC3-5EB1-4144-8CD9-BEADF988D51F

Q24243219-4ADCAFBF-7100-4E5A-919A-F828304D1269

Q24243219-5FEADB2F-2921-483A-B92C-7279C28FAB03

P31

Q24243219-589E8A4A-6E27-404A-8C2B-A4AA9A7AEAEF

Q24243219-cc5acccc-8886-41a2-a933-8079bb5f9ec3

P356

Q24243219-9D216C41-6EA1-4439-B58E-63B360AADC03

P50

Q24243219-8ADB490F-4C18-46B7-92ED-DBE1A3CB586F

P577

Q24243219-45F73ACF-65D5-4618-9E83-9BC902CE300E

P698

Q24243219-FEA57DF2-D68B-4654-A203-DF1BF37DA2F8

P356

14651858.CD000478.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

@en

P2093

John K MacDonald

http://www.w3.org/2001/XMLSchema#string

John WD McDonald

http://www.w3.org/2001/XMLSchema#string

P2860

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

A national survey on the patterns of treatment of inflammatory bowel disease in Canada

Measuring inconsistency in meta-analyses

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists.

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

Azathioprine for maintaining remission of Crohn's disease.

Tolerability of aminosalicylates in inflammatory bowel disease.

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.

P31

scholarly article

P356

10.1002/14651858.CD000478.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17253451

http://www.w3.org/2001/XMLSchema#string